Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasiti...(l prove to be accurate. Investorsshould ...),Health

Date:8/27/2007

l prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the Securities and Exchange Commission and available at http://www.sec.gov.

Contacts:

Media/Corporate: Investors:

GendeLLindheim BioCom Partners Samantha Haynes

Barbara Lindheim 800-539-0289

212 918-4650 info@upstreambio.com

'/>"/>

SOURCE Upstream Biosciences Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials